Official UK procurement notice
Manufacture of vaccine clinical lot
Authority: University Of York (Pelican) (Education)
What is being bought
Published requirement descriptionManufacture of a clinical lot of leishmaniasis vaccine
CPV: Research and development services and related consultancy services
The lotProcurement structure
single lot · no lot value publishedLot #1Manufacture of a clinical lot of leishmaniasis vaccine covering; Compatability study:…
Manufacture of a clinical lot of leishmaniasis vaccine covering; Compatability study: Production and Testing of Tox Lot, Clinical Material: GMP Production and Testing of Drug Substance (DS), Clinical Material: Production and Testing of Drug Product (DP), Clinical Material:
Procedure terms & legal framework
From the official record- Procedure method
- Negotiated without publication of a contract notice
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Services
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 1 Jun 2022, 12:36 BST
- Last source update
- 1 Jun 2022, 12:36 BST
- FTS notice number
2022/S 000-015336- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-03428eFind a Tender
- Why no open competition
The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
- Published justification
The University of York (including its associated entities) intends to contract with the enclosed provider for the manufacture of a vaccine clinical lot for a 42 month period commencing 1st July 2022 without a call for competition. The University's reasons are:
- The clinical lot is required to be compatible in manufacture with that previously used in clinical trials by the University of York, requiring manufacture using the cell line "Procell 92". The contractor were co-designers of the vaccine used in the clinical trials.
- Only the contractor is authorised by the owners of Procell 92 (GSK) to use this cell line for manufacture of a Leishmaniasis vaccine
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| ADVENT SRLSME | £1,072,764 † | — | Awarded |
Contracts
Contract 015336-2022-1 · ADVENT SRLSME
- Signed
- 1 Jun 2022
- Value
- £1,072,764
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Royal Courts of JusticeReview body
Bidders & participating suppliers
1 commercial party on the notice- ADVENT SRLAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.